Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged between 18 to 60 years~* Patients with ARVI, including influenza, starting not later than for 1 day prior to inclusion in the study:~* The body temperature measured axillary above 37.2 °C~* Presence of one of the signs of respiratory disease (runny nose, cough, pain / tickling in the throat)~* Presence of one of the systemic symptoms (weakness, myalgia, headache , chills, sweating)~* Provide written informed consent~* Ability to understand the nature of the study and provide written informed consent in accordance with Good Clinical Practice (GCP) and local law~Exclusion Criteria:~* Age over 60 years and under 18 years old~* Presence of allergic reactions~* Intolerance to NSAIDs and iodine-containing drugs~* Hypersensitivity to the components of the drug~* Mental illness that impedes compliance with the research procedure~* Pregnancy or breast-feeding~* Presence of acute, clinically significant respiratory and cardio vascular insufficiency, functional disorders of liver, kidney, digestive tract (ulcer disease) determined at physical examination or by laboratory screening tests~* Presence of congenital defects or serious chronic disease of the lungs, kidneys, cardiovascular system, nervous system, metabolic disorders, psychiatric disorders, confirmed by patients history or during initial examination~* The use of preparations of blood cytokine immunoglobulin in for 3 months prior to the study~* Chronic use of alcohol and / or drugs~* Presence or history of cancer diseases, HIV, hepatitis B and C~* Application of immunosuppressive or immunomodulatory drugs for 6-months prior to the study~* Women of child-bearing potential and who do not use acceptable measure of contraception or do not plan to use those throughout the study~* Any clinical condition that, according to the investigator, will not allow to safely carry out the protocol and take the studied drugs without risk to health~* Patients receiving antiviral therapy,~* Participation in other clinical trials at the present time or during the last 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 - Active Treatment (Type: EXPERIMENTAL): Patient who were randomized into Group 1 ingested Amizon tablets 0.5 g (2 tablets) after a meal, 3 times a day, for 7 days; each tablet contains 0.25 g of enisamium iodide.
- Group 2 - Placebo (Type: PLACEBO_COMPARATOR): Patient who were randomized into Group 2 ingested placebo tablets after a meal, at the dose 0.5 g (2 tablets), 3 times a day, for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).